Associated Papers
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.
de With M et al.
Esmo Open, 2023
36989883 (PubMed )
Supplement: mmc2.pdf
Identification of DPYD variants and estimation of uracil and dihydrouracil in a healthy Indian population.
Sivamani P et al.
Personalized Medicine, 2023
Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door.
Donadio MDS et al.
Ecancermedicalscience, 2022
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Vivaldi C et al.
The Pharmacogenomics Journal, 2021
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Hamzic S et al.
Pharmacological Research, 2020
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2018
Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma.
Velez-Velez LM et al.
Frontiers in Pharmacology, 2018
Select a paper to view details